The CDC's advisory committee unanimously recommended approval of Moderna and Johnson & Johnson booster doses on Thursday Members also approved of fully vaccinated Americans getting a booster dose different than their initial vaccine
The Centers for Disease Control and Prevention’s (CDC) advisory committee officially recommended boosters doses of the Moderna and Johnson & Johnson vaccines on Thursday.
The members of the Advisory Committee on Immunization Practices (ACIP) voted unanimously to give J&J’s extra doses to adults aged 18 and older and Modena’s third shot to those aged 65 and older or at high risk due to underlying conditions or their jobs
ACIP also recommended that fully vaccinated Americans be able to ‘mix and match’ Covid vaccines and booster shots.
This means people can receive a booster made by a company that is different than the one that made the vaccine they initially received.
Until the FDA announced its decision, ACIP was unable to recommend third doses, a necessary step before pharmacists or clinicians can immunize patients.
The CDC is not bound to follow the advisory group’s recommendations, but the agency rarely goes against the guidance of ACIP.
The CDC’s advisory committee unanimously recommended approval of Moderna and Johnson & Johnson booster doses on Thursday. Pictured: Nurse Elyse Isopo receives COVID-19 Pfizer vaccine booster at Teaching Center LIJ Medical Center in New York, September 23
Moderna’s (left) third dose is only authorized for those aged 65 and older or those between ages 18 and 64 at high risk due to underlying conditions or their jobs. J&J’s (right) booster shot is approved for all American adults aged 18 and older
J&J’s authorization comes after the company published data in September looking at the effectiveness of a second dose given 56 days after the first in adults 18 and older.
Results showed a booster shot was 94 percent effective against symptomatic COVID-19 and 100 percent effective against critical illness at least 14 days post-vaccination.
This compares to 70 percent protection seen with a single dose.
There was only one case of COVID-19 in the vaccine group and 14 in the placebo group.
J&J said that a booster given two months after the first dose increased antibody levels between four-fold and six-fold.
When given six months after the first dose, antibody levels shot up nine-fold after one week and 12-fold after four weeks.
In the case of Moderna, the company released data in September showing people who received its COVID-19 vaccine last year are nearly twice as likely to get a breakthrough infection compared to those recently vaccinated.
This is a breaking news story and will be updated.